聚势大湾区 链接长三角！广州邀沪企共拓生物医药新机遇

Core Viewpoint - The biopharmaceutical industry in China is experiencing rapid growth, driven by government support, technological innovation, and increasing healthcare demands, with Guangzhou positioning itself as a strategic hub for this sector [1][2]. Group 1: Industry Development and Support - Guangzhou has identified "biopharmaceuticals and health" as a strategic industry cluster, planning to focus resources over the next five years to enhance its development [1]. - The city has established a comprehensive financial support ecosystem, with Guangzhou Financial Holdings Group setting up over 20 billion yuan in funds to support biopharmaceutical projects, having invested in 228 projects totaling over 7 billion yuan [3]. - The "Hong Kong-Macao Drug and Device Pass" policy has facilitated the approval of 120 urgently needed drugs and devices, benefiting over 13,000 patients and expanding market opportunities for biopharmaceutical companies [5]. Group 2: Innovation and Ecosystem - Guangzhou is home to over 6,500 biopharmaceutical and health enterprises, leading in enterprise quantity, industry scale, and innovation capabilities nationally [6]. - The city has developed a full industry chain ecosystem covering research, manufacturing, and services, which has successfully transitioned biopharmaceutical innovations from laboratories to production lines [6]. - A series of supportive policies, including talent rewards and funding for research and commercialization, have been implemented to promote high-quality development in the biopharmaceutical sector, with a maximum support amount of 5 billion yuan [6][7]. Group 3: Regional Collaboration and Future Outlook - The collaboration between the Guangdong-Hong Kong-Macao Greater Bay Area and the Yangtze River Delta is seen as a dual engine for national biopharmaceutical development, with calls for enhanced regional cooperation and policy exchange [7]. - The recent roadshow in Shanghai serves as a platform for Guangzhou to showcase its biopharmaceutical cluster advantages and attract investment, aiming to build a world-class biopharmaceutical industry group [8].